本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SAN FRANCISCO, June 18, 2025 /PRNewswire/ -- The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare. The Tungs' Taichung MetroHarbor Hospital in Taiwan, in collaboration with AESOP Technology, conducted research on an AI-driven Clinical Decision Support System (CDSS) that leverages RWD to enable safer and more effective clinical decision-making, significantly reducing the risk of potentially inappropriate medications. The findings were published in the Journal of Medical Internet Research recently. RWD encompasses various data types, including electronic health records (EHR), insurance claims, wearable devices, environmental factors, and social determinants of health. It offers a comprehensive view of patient conditions and treatment outcomes. However, effectively utilizing RWD remains a significant challenge. As a key component of RWD, the EHR system is often constrained by the poor design of traditional CDSS. These systems frequently fire irrelevant or low-priority alerts and fail to provide specific recommendations for complex scenarios, such as off-label drug use, multimorbidity, and polypharmacy. This results in alert fatigue among physicians, causing critical alerts and reminders to be overlooked. Consequently, the completeness and accuracy of medical records are compromised, increasing the risk of inappropriate diagnoses or treatments and potentially threatening patient safety. This study addresses these challenges with an integrated AI-powered CDSS that combines MedGuard (now called RxPrime) for prescription appropriateness and DxPrime for diagnostic recommendations. By analyzing 438,558 prescriptions during a year-long trial, the system delivered 10,006 actionable recommendations, achieving a nearly 60% acceptance rate by physicians. Compared to traditional systems, this AI-enhanced approach demonstrated superior precision and practical applicability in real-world clinical settings. The results also revealed high acceptance rates in specialties such as ophthalmology (96.59%) and obstetrics/gynecology (90.01%), indicating strong applicability. In contrast, lower acceptance rates in neurology (38.54%) and hematology-oncology (10.94%) underscore the need for specialty-specific customization to address diverse clinical demands. This research highlights the transformative potential of RWD-driven AI systems with actionable recommendations to improve patient safety and support complex treatment decisions. These advancements foster greater trust and adoption of CDSS by physicians. Furthermore, by enhancing the completeness and accuracy of medical records, these systems elevate the quality of RWD, fostering a positive feedback loop that drives future medical advancements and consistently provides a reliable foundation for data-driven healthcare. About AESOP Technology AESOP Technology harnesses the power of AI to revolutionize clinical decision-making through its Clinical Diagnostic Reasoning Network model. By enhancing the accuracy of diagnoses, medication prescriptions, and medical coding, AESOP aims to improve patient safety and streamline healthcare processes. Its innovative solutions seamlessly integrate with EHR systems to boost efficiency and minimize errors, setting a new standard in medical care.
The award recognizes MINT for enabling real-time, end-to-end visibility across critical supply chain transactions and processes BOSTON, July 1, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, today announced that its Multienterprise Information Network Tower (MINT) solution has been named "Supply Chain Transparency Solution of the Year" in the 2025 SupplyTech Breakthrough Awards. The award recognizes MINT for advancing digital transformation in supply chain operations and enabling fully digitalized, integrated, and agile supply chains worldwide. MINT digitalizes global supply chains using TraceLink's proven network and its powerful B2N Integrate-Once™ capability to orchestrate end-to-end business transactions across commerce, direct supply, external manufacturing, logistics, transportation, and other complex multienterprise processes. Using pre-built integrations with leading procurement and supply chain hubs such as GHX and Ariba, MINT rapidly accelerates customers' time-to-value by radically reducing integration complexity. Powered by the industry's only no-code Orchestration Platform for Universal Solutions (OPUS), MINT enables a fundamental shift towards process and partner visibility while creating the continuously-flowing, real-time network data required for GenAI transformation. "Supply chains are subject to a wide range of dynamic challenges that demand reliable, sustainable, and metadata-driven network orchestration solutions," said Shabbir Dahod, President and CEO of TraceLink. "With MINT, we're offering scalable and affordable integration and data exchange across 100% of our customers' end-to-end trade partner network, including biopharmaceutical and medical device manufacturers, pharmacies, hospitals, wholesalers, 3PLs, CMOs, and materials suppliers. It is only through an end-to-end approach that measurable business outcomes like increased agility, improved operational efficiency, and ultimately, enhanced patient safety can be delivered." MINT's winning approach to network integration is simple: to participate, no customer or trading partner needs to change, modify, or retire their existing enterprise system or process. Through the use of TraceLink's proven B2N Integrate-Once™ universal integration capability, companies exchange data in any desired format (e.g., EDI [ANSI X12, EDIFACT], SAP IDoc, CSV, etc.), using any preferred method of data exchange, including B2B [AS2, SFTP, SMTP, HTTPS], API, email, or UI. This flexibility is even further enhanced through OPUS Link Actions and transforms, which companies leverage as pre-built connectors with many ERP systems such as NetSuite and Microsoft Dynamics. By enabling all companies to participate on the network using their existing tools and capabilities, TraceLink empowers customers to build their own GenAI-ready foundation for intelligent supply chain agents. With MINT, organizations gain actionable insights that improve revenue predictability, optimize inventory, and drive agile, resilient growth. The SupplyTech Breakthrough Awards, conducted annually by Tech Breakthrough, honor the top technology companies, solutions, and products across the global supply chain industry. The program aims to highlight the most innovative and impactful advancements in supply chain technology and services. TraceLink continues to set the standard for leadership and innovation in supply chain orchestration. To learn more about TraceLink and its solutions, please visit: https://www.tracelink.com/. About TraceLinkTraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely. To learn more, visit www.tracelink.com.
CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform. Combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive body contouring treatments: Accent Prime (Credit: Alma PR) Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed. This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention. "This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients." About Alma Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations. Media Inquiries:prglobal@almalasers.com
CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform. Combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive body contouring treatments: Accent Prime (Credit: Alma PR) Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed. This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention. "This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients." Accent Prime combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive treatments for body contouring, skin tightening, and facial rejuvenation. The platform is CE marked and approved for the treatment of various different indications, including facial and body contouring, skin tightening, cellulite reduction, and skin rejuvenation. Widely adopted by leading clinics worldwide, Accent Prime offers flexible, combination-based protocols that support tailored treatment strategies across diverse skin types and body areas—without the need for surgery or downtime. These proprietary ultrasound and radiofrequency technologies have also been clinically validated in other products from Alma's Body Contouring series, such as Alma PrimeX. About Alma Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations. Media Inquiries:prglobal@almalasers.com Photo - https://mma.prnasia.com/media2/2711970/Alma.jpg?p=medium600Logo - https://mma.prnasia.com/media2/2047372/5372311/Alma_Logo.jpg?p=medium600
CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with abdominal obesity, following a series of ultrasound and radiofrequency treatments using Alma's Accent Prime platform. Combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive body contouring treatments: Accent Prime (Credit: Alma PR) Conducted at Ewha Womans University Seoul Hospital by Dr. Yeo Ju Sohn and Dr. Hyejin Chun of the Department of Family Medicine at Ewha Womans University College of Medicine, the research confirmed measurable fat layer reduction through ultrasound imaging and waist circumference assessments. Patients reported high satisfaction and consistently strong tolerance throughout the treatment protocol, with no adverse events observed. This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond surgical intervention. "This study highlights the evolving role of non-invasive modalities in body shaping and reinforces their potential significance in the broader context of health and wellness," said Lior Dayan, CEO of Alma. "This new publication strengthens the scientific foundation supporting Alma's technologies and showcases our commitment to advancing innovation that prioritizes patient safety, enhances the treatment experience, and keeps pace with the evolving needs of modern patients." Accent Prime combines proprietary ultrasound and radiofrequency technologies to deliver personalized, non-invasive treatments for body contouring, skin tightening, and facial rejuvenation. The platform is CE marked and approved for the treatment of various different indications, including facial and body contouring, skin tightening, cellulite reduction, and skin rejuvenation. Widely adopted by leading clinics worldwide, Accent Prime offers flexible, combination-based protocols that support tailored treatment strategies across diverse skin types and body areas—without the need for surgery or downtime. These proprietary ultrasound and radiofrequency technologies have also been clinically validated in other products from Alma's Body Contouring series, such as Alma PrimeX. About Alma Alma is a global leader in medical aesthetic solutions, with over 25 years of innovation. We empower practitioners to deliver safe, effective, and life-transforming treatments to their patients, utilizing state-of-the-art, clinically proven solutions such as energy-based device lasers, diagnostics, injectables, and advanced skincare. Alma's multiple award-winning products have set a new benchmark in the medical aesthetic industry, both in terms of clinical excellence and groundbreaking innovations. Media Inquiries:prglobal@almalasers.com
ZHUBEI CITY, June 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology, a medical robotics company founded in 2015 in Taiwan by surgeon and serial entrepreneur Jerry Chen, has reached another major milestone. Following previous approvals from the Taiwan Food and Drug Administration (TFDA) and the CE Mark for Europe, Brain Navi has now received FDA 510(k) clearance for its stereotaxic guiding surgical device, NaoTrac — reinforcing our commitment to innovation, patient safety, and continuous improvement in the neurosurgical field. Dr. Jerry Chen, CEO of Brain Navi, announced the clearance of NaoTrac in U.S FDA For Brain Navi, this is a significant step forward, opening the door to new high-potential markets while affirming the quality and reliability of NaoTrac, our flagship robotic system. This milestone not only expands our global footprint but also validates the years of clinical research and development invested in the technology. We have received FDA 510(k) clearance, which confirms that NaoTrac is substantially equivalent in safety and effectiveness to legally marketed devices in the U.S. This recognition enables us to bring NaoTrac to U.S. hospitals and surgical teams, helping them achieve even higher levels of precision and efficiency in the operating room and save more lives. Key Features of NaoTrac Autonomous Navigation: SMART technology enables non-contact, frameless registration by aligning the patient's anatomy with preoperative imaging in seconds. Robotic Precision: The robotic arm assists neurosurgeons in positioning surgical instruments along a planned trajectory, ensuring optimal precision while allowing the surgeon to remain in control. Versatile Clinical Applications: NaoTrac supports a wide range of neurosurgical procedures, including biopsies, tumor ablations, endoscopic interventions, EVD placement, SEEG, and Deep Brain Stimulation (DBS). NaoTrac combines advanced robotic automation with AI-driven accuracy, aiming to elevate neurosurgical outcomes and improve safety for both surgeons and patients. This step marks a before-and-after moment for Brain Navi — one that paves the way for broader international adoption. As we move forward, we expect to see more and more NaoTrac systems installed around the world, supporting surgical teams and improving patient care across borders.
A12 藝術空間
patient safety
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
